Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction).

Published on May 7, 2014in Cochrane Database of Systematic Reviews7.89
· DOI :10.1002/14651858.CD003747.PUB4
Raza Alikhan14
Estimated H-index: 14
(University Hospital of Wales),
Rachel Forster8
Estimated H-index: 8
(Edin.: University of Edinburgh)
+ 0 AuthorsAlexander T. Cohen59
Estimated H-index: 59
(King's College)
Sources
Abstract
Background Venous thromboembolic disease has been extensively studied in surgical patients. The benefit of thromboprophylaxis is now generally accepted, but it is medical patients who make up the greater proportion of the hospital population. Medical patients differ from surgical patients with regard to their health and the pathogenesis of thromboembolism and the impact that preventative measures can have. The extensive experience from thromboprophylaxis studies in surgical patients is therefore not necessarily applicable to non-surgical patients. This is an update of a review first published in 2009. Objectives To determine the effectiveness and safety of heparin (unfractionated heparin or low molecular weight heparin) thromboprophylaxis in acutely ill medical patients admitted to hospital, excluding those admitted to hospital with an acute myocardial infarction or stroke (ischaemic or haemorrhagic) or those requiring admission to an intensive care unit. Search methods For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched November 2013) and CENTRAL (2013, Issue 10). Selection criteria Randomised controlled trials comparing unfractionated heparin (UFH) or low molecular weight heparin (LMWH) with placebo or no treatment, or comparing UFH with LMWH. Data collection and analysis One review author identified possible trials and a second review author confirmed their eligibility for inclusion in the review. Two review authors extracted the data. Disagreements were resolved by discussion. We performed the meta-analysis using a fixed-effect model with the results expressed as odds ratios (ORs) with 95% confidence intervals (CIs). Main results Sixteen studies with a combined total of 34,369 participants with an acute medical illness were included in this review. We identified 10 studies comparing heparin with placebo or no treatment and six studies comparing LMWH to UFH. Just under half of the studies had an open-label design, putting them at a risk of performance bias. Descriptions of random sequence generation and allocation concealment were missing in most of the studies. Heparin reduced the odds of deep vein thrombosis (DVT) (OR 0.41, 95% CI 0.25 to 0.67; P = 0.0004) . The estimated reductions in symptomatic non-fatal pulmonary embolism (PE) (OR 0.46; 95% CI 0.20 to 1.07; P = 0.07), fatal PE (OR 0.71; 95% CI 0.43 to 1.15; P = 0.16) and in combined non-fatal PE and fatal PE (OR 0.66, 95% CI 0.43 to 1.02; P = 0.06) associated with heparin were imprecise. Heparin resulted in an increase in major haemorrhage (OR 1.65, 95% CI 1.01 to 2.71; P = 0.05). There was no clear evidence that heparin had an effect on all-cause mortality and thrombocytopaenia. Compared with UFH, LMWH reduced the risk of DVT (OR 0.77; 95% CI 0.62 to 0.96; P = 0.02) and major bleeding (OR 0.43; 95% CI 0.22 to 0.83; P = 0.01). There was no clear evidence that the effects of LMWH and UFH differed for the PE outcomes, all-cause mortality and thrombocytopaenia. Authors' conclusions The data from this review describe a reduction in the risk of DVT in patients presenting with an acute medical illness who receive heparin thromboprophylaxis. This needs to be balanced against an increase in the risk of bleeding associated with thromboprophylaxis. The analysis favoured LMWH compared with UFH, with a reduced risk of both DVT and bleeding.
📖 Papers frequently viewed together
1,246 Citations
5,745 Citations
20128.31Chest
1,817 Citations
References76
Newest
BACKGROUND Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but the safety and efficacy of primary thromboprophylaxis in cancer patients treated with chemotherapy is uncertain. This is an update of a review first published in February 2012. OBJECTIVES To assess the efficacy and safety of primary thromboprophylaxis for VTE in ambulatory cancer patients receiving chemotherapy compared with placebo or no thromboprophylaxis....
148 CitationsSource
#1Ke-Zhou Dong (Nanjing University of Chinese Medicine)H-Index: 1
#2Yan-Zhi Song (Fudan University)H-Index: 1
Last. Yi-Min Zhu (Nanjing University of Chinese Medicine)H-Index: 1
view all 7 authors...
Background Venous thromboembolism (VTE) is a common condition with potentially serious and life-threatening consequences. The standard method of thromboprophylaxis uses an anticoagulant such as low molecular weight heparin (LMWH) or warfarin. In recent years, another type of anticoagulant, pentasaccharide, an indirect factor Xa inhibitor, has shown good anticoagulative effect in clinical trials. Three types of pentasaccharides are available: short-acting fondaparinux, long-acting idraparinux and...
9 CitationsSource
#1Peter Sandercock (Edin.: University of Edinburgh)H-Index: 106
#2Carl Counsell (Aberd.: University of Aberdeen)H-Index: 51
Last. Edward J Kane (Edin.: University of Edinburgh)H-Index: 1
view all 3 authors...
Background Most ischaemic strokes are caused by blood clots blocking an artery in the brain. Clot prevention with anticoagulants might improve outcome if bleeding risks were low. This is an update of a Cochrane review first published in 1995, and previously updated in 2004. Objectives To assess the effect of anticoagulant therapy versus control in the early treatment (less than 14 days) of patients with acute ischaemic stroke. Search methods We searched the Cochrane Stroke Group Trials Register ...
293 CitationsSource
1,144 Citations
#1Sandercock PagH-Index: 1
#2Counsell CH-Index: 1
Last. Kane EjH-Index: 1
view all 3 authors...
5 Citations
#1Alexander T. Cohen ('KCL': King's College London)H-Index: 41
#1Alexander T. Cohen ('KCL': King's College London)H-Index: 59
Last. Victor F. Tapson (Duke University)H-Index: 94
view all 11 authors...
A total of 8101 patients underwent randomization. A primary efficacy outcome event occurred in 78 of 2938 patients (2.7%) receiving rivaroxaban and 82 of 2993 patients (2.7%) receiving enoxaparin at day 10 (relative risk with rivaroxaban, 0.97; 95% confidence interval [CI], 0.71 to 1.31; P = 0.003 for noninferiority) and in 131 of 2967 patients (4.4%) who received rivaroxaban and 175 of 3057 patients (5.7%) who received enoxaparin followed by placebo at day 35 (relative risk, 0.77; 95% CI, 0.62 ...
402 CitationsSource
#1Gordon H. GuyattH-Index: 260
#2Elie A. AklH-Index: 96
Last. Holger J. Schu¨nemannH-Index: 3
view all 5 authors...
T article provides the rationale for the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (AT9) approach to estimating the effect of antithrombotic prophylaxis on patient-important outcomes of pulmonary embolism (PE) and symptomatic venous thrombosis. 1.0 Thromboprophylaxis Reduces Fatal PE in Medical and Surgical Patients
233 Citations
#1Walter Ageno (University of Insubria)H-Index: 70
#2Alex C. SpyropoulosH-Index: 46
Last. Alexander G.G. TurpieH-Index: 110
view all 3 authors...
Anticoagulation therapy for the prevention of venous thromboembolic events is indicated in patients after major orthopaedic surgery and in hospitalised acutely ill medical patients, who have a high or moderate risk of venous thromboembolism (VTE), respectively. Clinical trials have clearly demonstrated that short-term anticoagulation reduces the risk of VTE in these patient groups and that longer-term anticoagulation is beneficial for some indications. Evidence-based guidelines for thromboprophy...
21 CitationsSource
#1Clive Kearon (McMaster University)H-Index: 91
#2Elie A. Akl (UB: University at Buffalo)H-Index: 96
Last. Susan R. Kahn (McGill University)H-Index: 84
view all 12 authors...
Background: This guideline focuses on antithrombotic drug therapies for primary and secondary prevention of cardiovascular disease as well as for the relief of lower-extremity symptoms and critical ischemia in persons with peripheral arterial disease (PAD). Methods: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College ...
4,898 CitationsSource
#1Susan R. Kahn (McGill University)H-Index: 84
#1Yngve Falck-Ytter (Case Western Reserve University)H-Index: 57
Last. M. Hassan Murad (Mayo Clinic)H-Index: 88
view all 9 authors...
Background: VTE is a serious, but decreasing complication following major orthopedic surgery. This guideline focuses on optimal prophylaxis to reduce postoperative pulmonary embolism and DVT. Methods: The methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in...
1,817 CitationsSource
Cited By85
Newest
#1Daniel Horner (University of Manchester)H-Index: 8
#2Steve Goodacre (University of Sheffield)H-Index: 55
Last. Beverley J. Hunt (Guy's and St Thomas' NHS Foundation Trust)H-Index: 79
view all 5 authors...
### What you need to know Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major global health burden. North American data report a 30 day case fatality rate of 10.6% following VTE. Between 30% and 50% of survivors go on to have long term complications.12 About half of VTE episodes occur during hospitalisation for surgery or acute medical illness, or within 90 days from discharge. These events are classified as hospital acquired thrombosis...
Source
#1Matti Sievert (FAU: University of Erlangen-Nuremberg)H-Index: 2
#2Miguel Goncalves (FAU: University of Erlangen-Nuremberg)H-Index: 10
Last. Claudia Scherl (FAU: University of Erlangen-Nuremberg)H-Index: 8
view all 8 authors...
PURPOSE Free flap reconstruction is a valuable technique to preserve function in oncological head and neck surgery. Postoperative graft thrombosis is a dreaded risk. This study aims to compare low-dose unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) in perioperative thrombosis prophylaxis. METHODS This is a retrospective analysis of 266 free flaps performed at our academic center. A comparison was made between 2 patient groups, based on their respective postoperative prophyl...
Source
Deep vein thrombosis (DVT) is the formation or presence of a thrombus in the deep veins. DVT occurs mostly in the lower extremities and to a lesser extent in the upper extremities. Pulmonary embolism (PE) is an obstruction of the pulmonary artery or its branches by a thrombus (sometimes due to fat or air). The most likely source of thrombus in pulmonary arteries is an embolization from deep veins of the legs. This occurs in one-third of patients with DVT. Prevention of DVT thereby decreases the ...
#1Gary H. Lyman (Fred Hutchinson Cancer Research Center)H-Index: 117
#2Marc Carrier (Ottawa Hospital Research Institute)H-Index: 60
Last. Pablo Alonso-Coello (Cochrane Collaboration)H-Index: 69
view all 16 authors...
BACKGROUND Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality. OBJECTIVE These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer. METHODS ASH formed a multidisciplinary guideline panel balance...
2 CitationsSource
#1A.C. Budd (U of S: University of Saskatchewan)
#2M. Rhodes (Ottawa Hospital Research Institute)H-Index: 1
Last. P. S. Wells (Ottawa Hospital Research Institute)H-Index: 11
view all 6 authors...
Abstract Guidelines suggest broad use of pharmacologic prophylaxis to prevent venous thromboembolism (VTE) in hospitalized medical patients, however little ‘real-world’ data exists to support this. Our goal was to describe the use of thromboprophylaxis among general medical and cancer patients admitted to hospital, compare VTE and bleeding outcomes according to use of thromboprophylaxis, and to determine what variables influence prescribing patterns and outcomes. Patients admitted to the general...
Source
#1Anat Gafter-Gvili (TAU: Tel Aviv University)H-Index: 19
#1Anat Gafter-Gvili (TAU: Tel Aviv University)H-Index: 30
Last. Leonard Leibovici (Rabin Medical Center)H-Index: 9
view all 5 authors...
Abstract Objectives Current guidelines recommend pharmacologic prophylaxis for medical patients at high risk for venous thromboembolism. We aimed to assess the benefit and safety of venous thromboembolism prophylaxis in acutely ill medical patients hospitalized. Methods Retrospective cohort study in a tertiary hospital in Israel. Patients hospitalized in medical departments with an admission lasting more than 48 hours during 2014-2017. Primary outcome: 30-day mortality. Secondary outcomes: 90 da...
2 CitationsSource
#1David Feinbloom (Harvard University)H-Index: 4
#2Jason A. Freed (Harvard University)H-Index: 7
Last. Shoshana J. Herzig (Harvard University)H-Index: 19
view all 6 authors...
Low-dose unfractionated heparin (LDUH) prophylaxis decreases the incidence of venous thromboembolism (VTE) in hospitalized patients, but increases the risk of bleeding events. Patients who develop a prolonged activated partial thromboplastin time (aPTT) while on LDUH may be at higher risk for bleeding complications. To determine the incidence and risk factors for aPTT prolongation in hospitalized patients receiving LDUH thromboprophylaxis, we performed a retrospective pharmacoepidemiologic cohor...
Source
#1Lara N. Roberts (University of Cambridge)H-Index: 18
#2Martin Whyte (University of Cambridge)H-Index: 15
Last. Roopen Arya (University of Cambridge)H-Index: 28
view all 10 authors...
The association of severe COVID-19 with an increased risk of VTE has resulted in specific guidelines for its prevention and management. The VTE risk appears highest in those with critical care admission. The need for post discharge thromboprophylaxis remains controversial and this is reflected in the conflicting recommendations of expert guidelines. Our local protocol provides thromboprophylaxis to COVID-19 patients during admission only. We report post-discharge VTE data from an ongoing quality...
29 CitationsSource
#1Agnès Ribes (University of Toulouse)H-Index: 2
#2Fanny Vardon-Bounes (University of Toulouse)H-Index: 6
Last. Bernard Payrastre (University of Toulouse)H-Index: 76
view all 11 authors...
Abstract The novel Corona virus infection (Covid-19) first identified in China in December 2019 has rapidly progressed in pandemic leading to significant mortality and unprecedented challenge for healthcare systems. Although the clinical spectrum of Covid-19 is variable, acute respiratory failure and systemic coagulopathy are common in severe Covid-19 patients. Lung is an important target of the SARS-CoV-2 virus causing eventually acute respiratory distress syndrome associated to a thromboinflam...
14 CitationsSource
#1Gabriel Pasquarelli-do-Nascimento (UnB: University of Brasília)H-Index: 2
#2Heloisa Antoniella Braz-de-Melo (UnB: University of Brasília)H-Index: 3
Last. Kelly Grace Magalhães (UnB: University of Brasília)H-Index: 20
view all 6 authors...
COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes, and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreover, countries with greater obesity prevalence have a higher morbidity and mortality risk of developing serious outcomes from COVID-19. The understanding of how this increased susceptibility of the p...
18 CitationsSource